Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EUSA Sylvant Licence Marks Toehold Into US Rare Disease Market

Executive Summary

Six months after selling its critical care business to refocus on rare diseases and oncology, EUSA Pharma has made its first move into those markets by licensing a Janssen product for a rare blood disorder.

You may also be interested in...

Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier

Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.

Video Interview: Getting to know EUSA Pharma 2.0

EUSA Pharma, initially formed in 2006 but later acquired by Jazz Pharmaceuticals in 2012, was reborn last year with a fresh new focus on specialty products in the oncology space. Business development director, Benjamin Owens, spoke with Scrip reporter Lucie Ellis about EUSA's big plans for global expansion. The pharma will target Spain, Italy and the Nordics in the near future and is also focused on securing a strong US presence through collaborations and acquisitions.

J&J/Janssen win OK for Sylvant; 1st US drug in Castleman's

Johnson & Johnson subsidiary Janssen gained FDA approval on 23 April for Sylvant (siltuximab), the first drug in the US to treat patients with multicentric Castleman's disease (MCD), a rare blood disorder in which lymphocytes are over-produced, leading to enlarged lymph nodes, and which also can affect the lymphoid tissue of internal organs, causing the liver, spleen or other organs to enlarge.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts